Phase Forward Announces FDA Contract Award for Production Rollout of WebSDM with Empirica Study

Phase Forward Announces FDA Contract Award for Production Rollout of WebSDM with Empirica Study

Contract Will Support Expanded Rollout of Phase Forward's WebSDM Product with Clinical Trials Signal Detection at FDA CDER

WALTHAM, Mass., Nov 02, 2009 (BUSINESS WIRE) -- Phase Forward (NASDAQ: PFWD), a leading provider of data management solutions for clinical trials and drug safety, today announced a contract award to support the FDA's production rollout of the company's WebSDM(TM) Release 3.0 software, including the Empirica(TM) Study Clinical Trials Signal Detection system. The WebSDM tool was originally developed under a Cooperative Research and Development Agreement (CRADA) for the FDA to validate and review submission data in CDISC Study Data Tabulation Model (SDTM) format, and has been installed at FDA since 2005. Empirica Study provides advanced statistical screening and visualization tools for review of SDTM data.
Under the contract, Phase Forward will be providing extended support, training, expanded statistical documentation for reviewers, software updates and enhancements to the Center for Drug Evaluation and Research's (CDER's) Computational Science Center (CSC) as it works to make standards-based review tools such as WebSDM more readily available to reviewers. The WebSDM solution is also installed at the National Cancer Institute (NCI) for use with the FDA's Janus data warehouse.

"We're very pleased to have this opportunity to help CDER expand reviewers' use of WebSDM to help them more fully realize the benefits of standardized submission data in CDISC format," said Wayne Kubick, vice president for Phase Forward's Lincoln Safety Group and Lincoln's principal investigator for the original CRADA. "Over the past year, we have seen increased interest among reviewers in using Empirica Study's advanced signal detection capabilities, including Multivariate Bayesian Logistic Regression and its rich set of graphical visualizations with drilldown to facilitate exploration of lab, ECG, vital signs, completion and adverse event data. This new contract will allow us to help reviewers further capitalize on the wider signal detection and analysis capabilities that these products can offer."

WebSDM, along with the Empirica(TM) suite of pharmacovigilance and risk management products, is managed by Phase Forward's Lincoln Safety Group, one of the most experienced and respected teams in the industry.

About Phase Forward

Phase Forward is a leading provider of integrated data management solutions for clinical trials and drug safety. Phase Forward's products and services have been utilized in over 10,000 clinical trials involving more than 1,000,000 clinical trial study participants at over 300 organizations and regulatory agencies worldwide including: AstraZeneca, Boston Scientific, Dana-Farber Cancer Institute, Eli Lilly, the U.S. Food and Drug Administration, GlaxoSmithKline, Harvard Clinical Research Institute, Merck Serono, Novartis, Novo Nordisk, PAREXEL International, Procter & Gamble, Quintiles, sanofi-aventis, Schering-Plough Research Institute, Servier, SGS, Tibotec and the U.K. Medicines and Healthcare Products Regulatory Agency. Additional information about Phase Forward is available at www.phaseforward.com.

 

Suggested Articles

I-MAB's anti-GM-CSF drug works "upstream" in inflammation pathways, potentially blocking several dangerous cytokines in COVID-19, executives…

Antibe's lead drug beat placebo at reducing osteoarthritis pain, boosting its case as an alternative to NSAIDs, commonly used to treat the condition.

The trial marks the start of a new phase of the response to SARS-CoV-2 in which people will receive drugs designed specifically for the virus.